HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

Japan’s FY26 price revision expands G1 repricing and drives price reduction

Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices on a spending basis across 15,800 products.

By Pharmaceutical Technology · May 8, 2026 · via Pharmaceutical Technology
Japan’s FY26 price revision expands G1 repricing and drives price reduction

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
policyformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
PolicyFiercePharma ↗
Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepr…
May 9, 2026
A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs
PolicyKFF Health News ↗
A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the m…
May 8, 2026
STAT+: More political interference at the FDA?
PolicySTAT News ↗
STAT+: More political interference at the FDA?
A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newslet…
May 7, 2026